D
Dongbao Pharmaceutical
Develops and markets recombinant human insulin for the treatment of diabetes
About Dongbao Pharmaceutical
Tonghua Dongbao Pharmaceutical Co., Ltd. is a leading biopharmaceutical company specializing in the development and commercialization of high-end recombinant protein products and treatments for endocrine and metabolic disorders. Operating primarily in the Chinese market, the company serves both consumer and professional healthcare sectors. Tonghua Dongbao's business model revolves around continuous innovation and upgrading of its technology platforms to expand its product line and market segments. The company generates revenue through the sale of its proprietary biopharmaceutical products, including recombinant human insulin and GLP-1 receptor agonists like liraglutide and semaglutide injections. Recent developments include the approval of 1RA Liraglutide injection for marketing and the acceptance of etoricoxib tablets by the NMPA. The company also focuses on sustainable practices such as acetonitrile recycling and wastewater treatment. Tonghua Dongbao's strategic partnerships and funding rounds aim to leverage expertise and resources to accelerate growth and ensure long-term success.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1994
- Headquarters
- Huangpu, China
- Employees
- 187
- Open positions
- 46
- Dealroom signal
- 37.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Drug Development, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Jan 2026
- Capital deployed
- $35M
- Preferred round
- SERIES B
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Sep 2020 | $283M | — | DCP Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Dongbao Pharmaceutical is 2.3K monthly website visits, up 180.5% over the last three months. Dongbao Pharmaceutical's team grew 2.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xinyao Paike Medical TechnologyHuangpu, ChinaHigh-end pharmaceutical packaging materials and medical devices
$55Mvaluation
Junhemeng BiopharmaceuticalHangzhou, ChinaA recombinant protein drug developer
$138Mvaluation
AMOYTOP BIOTECHXiamen, ChinaBiopharmaceutical leader in recombinant protein drugs for viral hepatitis, cancer, and immunotherapy solutions
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
DCP Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dongbao Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dongbao Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.